Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGSWW) EPS (Weighted Average and Diluted) (2020 - 2025)

GeneDx Holdings has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$0.61 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.61 for Q4 2025, down 365.22% from a year ago — trailing twelve months through Dec 2025 was -$0.75 (up 61.73% YoY), and the annual figure for FY2025 was -$0.73, up 62.37%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.61 at GeneDx Holdings, down from -$0.27 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for WGSWW hit a ceiling of $0.98 in Q4 2021 and a floor of -$348.82 in Q1 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$1.01 (2023), compared with a mean of -$22.71.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 4300.0% in 2022 and later skyrocketed 132.73% in 2025.
  • GeneDx Holdings' EPS (Weighted Average and Diluted) stood at $0.98 in 2021, then crashed by 3056.12% to -$28.97 in 2022, then soared by 96.82% to -$0.92 in 2023, then skyrocketed by 125.0% to $0.23 in 2024, then tumbled by 365.22% to -$0.61 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.61 (Q4 2025), -$0.27 (Q3 2025), and $0.36 (Q2 2025) per Business Quant data.